HyperGenomics Signs Contract for Provision of First Revenues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – HyperGenomics has signed a contract with an undisclosed partner that is expected to provide the firm with its first revenues, its parent firm VolitionRx said today.

The deal calls for Singapore-based VolitionRx to develop epigenetic profiling signatures from blood and makes HyperGenomics eligible for payments of up to a total of US$55,000 if milestones are met during the next eight months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.